OM-85

OM-85 or OM85 (trade name Broncho-Vaxom) is an immunostimulant. It is a combination of molecules extracted from the walls of bacteria that commonly cause respiratory infections.[1]

OM-85
Clinical data
Trade namesBroncho-Vaxom
Other namesOM 85BV
Identifiers
CAS Number

Uses

It has been sold, as Broncho-Vaxom, in Europe and some South American countries.[1] It is used for children with asthma or recurrent respiratory infections.[1]

Potential uses

It may help prevent Covid-19.[2]

It may prevent babies from developing asthma.[3][4]

Composition

It is a mix of lipopolysaccharides,[4] extracted from bacteria cell walls.

Clinical trials

It has been studied in numerous pediatric clinical trials.[2]

References
  1. Sly P (11 June 2020). "M85: could bacteria in a capsule protect us from coronavirus and other respiratory infections?".
  2. Cao C, Wang J, Li Y, Li Y, Ma L, Abdelrahim ME, Zhu Y (May 2021). "Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis". International Journal of Clinical Practice. 75 (5): e13981. doi:10.1111/ijcp.13981. PMC 7883224. PMID 33405321.
  3. Hart A (15 Feb 2022). "Aussie researchers make asthma breakthrough".
  4. Troy NM, Strickland D, Serralha M, de Jong E, Jones AC, Read J, et al. (July 2022). "Protection against severe infant lower respiratory tract infections by immune training: Mechanistic studies". The Journal of Allergy and Clinical Immunology. 150 (1): 93–103. doi:10.1016/j.jaci.2022.01.001. hdl:10044/1/95014. PMID 35177255. S2CID 246844791.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.